Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3497192

O=C(O)C(F)(F)F.O=C(O)c1cc(Br)cc(-c2cccnc2)c1

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.53
MKNK1 Q9BUB5 3/20 0.52
MKNK2 Q9HBH9 3/20 0.52
KDR P35968 3/20 0.46
CDC7 O00311 1/20 0.44
DBF4 Q9UBU7 1/20 0.44
ALDH1A1 P00352 1/20 0.44
APP P05067 1/20 0.44
GAA P10253 1/20 0.44
HCAR3 P49019 1/20 0.44
HCAR2 Q8TDS4 1/20 0.44
PDK2 Q15119 1/20 0.43
ERN1 O75460 1/20 0.41
ABL1 P00519 1/20 0.41
OPRM1 P35372 1/20 0.41
KCNH2 Q12809 1/20 0.41
IP6K1 Q92551 1/20 0.41
IP6K3 Q96PC2 1/20 0.41
IP6K2 Q9UHH9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5226019 0.92 KMO (0.67) KMOMKNK1MKNK2KDRALDH1A1
SCHEMBL10028699 0.81 KMO (0.77) KMOMKNK1MKNK2ALDH1A1APP
SCHEMBL17089048 0.81 KMO (0.77) KMOMKNK1MKNK2ALDH1A1APP
SCHEMBL29503876 0.81 KMO (0.77) KMOMKNK1MKNK2ALDH1A1APP
SCHEMBL3497193 0.81 KDR (0.44) KMOL3MBTL1MKNK1MKNK2KDR
SCHEMBL13044190 0.78 KMO (0.73) KMOMKNK1MKNK2ALDH1A1APP
SCHEMBL5229566 0.77 KMO (0.67) KMOMKNK1MKNK2ALDH1A1APP
SCHEMBL5229005 0.76 CYP19A1 (0.60) KMOMKNK1MKNK2ALDH1A1ABL1
SCHEMBL3496923 0.75 PDK2 (0.48) KMOMKNK1MKNK2KDRALDH1A1
Niacin SCHEMBL4718565 0.75 ALDH1A1 (0.78) KMOL3MBTL1MKNK1MKNK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160255-A1 SPIRO-CYCLIC COMPOUND ACACA, CPT1B, PC KMO 3580/4885L3MBTL1 1920/4885MKNK1 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.